Promega Executive and Leadership Team

Deanna Schuppel, the Senior Executive Administrator, Chief Executive Officer at Promega, manages critical administrative functions supporting the company's strategic direction. This role ensures operational efficiency and seamless execution of executive directives, aligning administrative processes with Promega's mission in biotechnology and molecular biology. Schuppel's oversight extends to coordinating executive communications and facilitating key decision-making workflows. The focus remains on optimizing support structures that enable Promega's continued impact in genomics, protein analysis, and cellular research. Deanna Schuppel's contributions are vital for maintaining the high standards of operational excellence required in the pharmaceutical manufacturing sector. This position directly supports the company's overarching goals of scientific advancement and product development, ensuring that administrative frameworks bolster research and discovery initiatives across global markets. The administrator's responsibilities are integral to the smooth functioning of the executive office, facilitating strategic planning and execution.

Les Louia, the President & Chief Executive Officer at Promega, directs the company's overall strategy and operational execution. Louia's leadership guides Promega's extensive portfolio in genomics, protein analysis, cellular analysis, drug discovery, and genetic identity. This executive steers the organization toward continued innovation and market leadership within the biotechnology and molecular biology sectors. Overseeing global operations, Les Louia ensures alignment with the company's founding principles and its commitment to advancing scientific research. The strategic vision implemented by Louia drives revenue growth and expands Promega's influence across key scientific disciplines. This leadership role involves fostering a culture of scientific inquiry and operational excellence, crucial for maintaining Promega's position as a premier manufacturer of essential research products. Les Louia's tenure is marked by a dedication to enhancing the company's impact on drug discovery and genetic identity solutions worldwide.

William Linton, the Chairman, Chief Executive Officer & President at Promega, provides foundational leadership and strategic oversight for the company's global operations. Linton's extensive experience shapes Promega's long-term vision, focusing on pioneering advancements in biotechnology and molecular biology. This executive guides the company's commitment to developing cutting-edge products for genomics, protein analysis, and cellular analysis. The strategic direction set by William Linton ensures Promega remains at the forefront of scientific innovation, particularly in drug discovery and genetic identity applications. Linton's leadership fosters a robust corporate culture dedicated to scientific integrity and market impact. This role involves steering the company through evolving scientific landscapes and maintaining its reputation for quality and reliability in the global market. William Linton's influence is critical in driving Promega's mission to empower researchers and accelerate scientific breakthroughs.

Chris Yarbro, the Chief Financial Officer at Promega, manages the company's financial operations and strategic fiscal planning. Yarbro oversees all aspects of financial reporting, budgeting, and investment, ensuring fiscal health and sustainable growth for Promega. This executive's responsibilities include optimizing financial performance across the company's diverse product lines in genomics, protein analysis, and cellular analysis. The financial strategies implemented by Chris Yarbro support Promega's ongoing research and development efforts in drug discovery and genetic identity. Yarbro plays a key role in capital allocation, risk management, and ensuring compliance with financial regulations. This leadership position is vital for maintaining Promega's financial stability and enabling strategic investments that drive innovation and market expansion. Chris Yarbro's expertise underpins the company's ability to fund critical scientific advancements.

Kristen Yetter, the General Manager and President at Promega, directs significant operational segments and drives business growth initiatives. Yetter oversees key functional areas, ensuring efficient execution of Promega's strategic objectives across its product lines in genomics, protein analysis, and cellular analysis. This executive focuses on optimizing operational performance and fostering cross-functional collaboration to enhance product delivery and customer satisfaction. The leadership provided by Kristen Yetter is crucial for translating Promega's scientific innovations into market-ready solutions for drug discovery and genetic identity. Yetter's responsibilities include managing P&L for designated business units and spearheading market expansion efforts. This role is vital for maintaining Promega's operational excellence and competitive positioning in the global biotechnology landscape. Kristen Yetter's strategic management ensures sustained business momentum and innovation.

Sandra Gardner, the Chief Information Officer at Promega, directs the company's technology strategy and digital infrastructure. Gardner oversees the implementation of advanced IT solutions that support Promega's extensive product portfolio in genomics, protein analysis, and cellular analysis. This executive ensures that information systems are robust, secure, and scalable, enabling efficient operations across all business functions. The focus is on leveraging technology to enhance research capabilities, streamline drug discovery processes, and improve genetic identity solutions. Sandra Gardner's leadership drives digital transformation initiatives, optimizing data management and cybersecurity measures. This role is critical for maintaining Promega's competitive edge in the biotechnology sector by ensuring seamless integration of technology with scientific objectives. Gardner's strategic guidance empowers the organization to harness data effectively for innovation and operational efficiency.

Kara Machleidt, the Global Chief Revenue Officer, Strategic Business Lead at Promega, drives revenue generation and oversees key strategic business initiatives. Machleidt leads global sales and business development efforts, focusing on expanding market reach for Promega's comprehensive suite of products in genomics, protein analysis, and cellular analysis. This executive is instrumental in identifying new market opportunities and strengthening customer relationships worldwide. The strategic business leadership provided by Kara Machleidt ensures alignment between revenue goals and the company's mission in drug discovery and genetic identity. Machleidt's role involves developing and executing go-to-market strategies that maximize commercial success. This position is critical for translating scientific innovation into tangible business growth and market penetration. Kara Machleidt's focus on strategic partnerships and revenue optimization fuels Promega's continued expansion.

Ash Anderson, the Chief Medical Officer at Promega, provides critical medical and scientific expertise to guide product development and research initiatives. Anderson oversees the clinical relevance and application of Promega's technologies, particularly in areas such as drug discovery and cellular analysis. This executive ensures that the company's offerings align with current medical needs and scientific advancements in biotechnology. The medical insights provided by Ash Anderson are crucial for validating the efficacy and utility of products in genomics and protein analysis. Anderson's role involves bridging the gap between scientific research and clinical application, ensuring Promega's solutions address real-world health challenges. This leadership position is vital for enhancing Promega's credibility and impact within the medical and scientific communities. Ash Anderson's contributions support the development of innovative tools for diagnostics and therapeutic research.